

Enactment 3

The physician has an older patient who is worried that he may be developing Alzheimer disease since he has a family history of dementia. The physician heard about a genetic test for APOE that may help predict risk of AD and was wondering whether it's a good idea or not to have the patient tested. Before the physician talks to the patient, he consults with a medical geneticist.

Genetic Testing Registry



Showing test for 1 condition

Enter text to filter the conditions

Select a condition

reset

Alzheimer disease, type 2

Alzheimer disease, type 3

Alzheimer disease, type 4

Alzheimer's disease

Amyloidogenic transthyretin amyloidosis

Andersen Tawil syndrome

Compare labs

▼ Test type

reset

☒ Clinical (9)

▼ Test purpose

☐ Diagnosis (8)

☐ Mutation Confirmation (1)

☐ Pre-symptomatic (1)

☐ Screening (1)

▼ Test method

Molecular Genetics (9)

☐ Sequence analysis of the entire coding region (5)

☐ Deletion/duplication analysis (1)

☐ Sequence analysis of select exons (2)

☐ Mutation scanning of select exons (1)

☐ Targeted variant analysis (3)

▼ Test services

☐ Carrier testing (1)

☐ Prenatal testing (1)

▼ Lab certification

Showing 1 to 9 of 9 tests for 1 condition in 6 labs

C Apolipoprotein E Gene Mutation

Methods: T Targeted variant analysis

Analytical Validity: Test was validated by testing at least 20 samples.

Lab: [Immuno-Molecular Pathology University of Kentucky](#)

Directors: C Jennings, MD, ABPath, FCAP, Lab Director

C Alzheimer: Apo-E, PSEN1, PSEN2, A2M and APP genes sequence analysis (select exons)

Methods: C Sequence analysis of the entire coding region

Analytical Validity: 99% sensitivity

Lab: [GENETAQ Molecular Genetics Centre and Diagnosis of Rare Diseases](#)

Directors: Juan Lopez, PhD, Scientific Director

C Alzheimer: Apo-E, PSEN1, PSEN2, APP, A2M and MAPT genes sequence analysis (select exons)

Methods: C Sequence analysis of the entire coding region

Analytical Validity: 99% sensitivity

Lab: [GENETAQ Molecular Genetics Centre and Diagnosis of Rare Diseases](#)

Directors: Juan Lopez, PhD, Scientific Director

C Alzheimer: MAPT, CLU, PICALM, CR1 genes screening

Methods: X Mutation scanning of select exons

Analytical Validity: 99% sensitivity

Lab: [GENETAQ Molecular Genetics Centre and Diagnosis of Rare Diseases](#)

Directors: Juan Lopez, PhD, Scientific Director

C APOE: ApoE gene genotyping

Methods: C Sequence analysis of the entire coding region

Analytical Validity: 99% sensitivity

Lab: [GENETAQ Molecular Genetics Centre and Diagnosis of Rare Diseases](#)

Directors: Juan Lopez, PhD, Scientific Director

Key concepts from Enactment 3

- GINA – what it does and doesn't cover
- Personal utility is increasingly being recognized as rationale for genetic testing
- Where to find information about available tests
- Utility of targeted variant analysis versus sequencing entire coding region